| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Risankizumab-rzaa | 2025-11-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Sarilumab | 2025-11-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Secukinumab | 2025-11-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Tildrakizumab-asmn | 2025-11-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Tocilizumab and Biosimilars | 2025-11-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Ustekinumab and Biosimilars | 2025-11-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Vedolizumab | 2025-11-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Flibanserin | 2025-11-01 |
| UHC UMR Medical and Drug | Buprenorphine (Brixadi® & Sublocade®) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Buprenorphine (Brixadi® & Sublocade®) – Commercial Medical Benefit Drug Policy | 2025-11-01 |